Omalizumab for anaphylaxis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Trials ended early. Its trials were stopped early. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 28 May 2019: Trial registered, NCT03964051
  2. 1 Jul 2019: Trial started, NCT03964051
  3. 21 Dec 2020: Trial terminated, NCT03964051

The trials

NCT03964051: Protection From Food Induced Anaphylaxis by Reducing the Serum Level of Specific IgE (Protana).

State
Stopped early
Phase
Phase 4
People
7 taking part
Started
1 Jul 2019
Primary completion
21 Dec 2020
Arms
Omalizumab 300 mg for s.c.injection
Results
None posted
  1. 28 May 2019: Trial registered
  2. 1 Jul 2019: Trial started
  3. 21 Dec 2020: Trial terminated

How the status changed

  1. 19 Nov 2026: First set: Trials ended early

About the treatment

Kind of treatment: Drug.

Also known as Omalizumab Injection, Xolair.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.